This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of -7.27% and 32.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 105.75% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 105.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Foghorn Therapeutics Inc. (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 124.3% upside potential for Foghorn Therapeutics Inc. (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of 27.85% and 17.59%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Silence Therapeutics PLC Sponsored ADR (SLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?
by Zacks Equity Research
Foghorn Therapeutics Inc. (FHTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development
by Zacks Equity Research
Foghorn (FHTX) gains 55% as its strategic collaboration partner, Lilly, selects the pre-clinical candidate, FHD-909, for clinical development.
Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's Why
by Zacks Equity Research
Foghorn Therapeutics Inc. (FHTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
How Much Upside is Left in Foghorn Therapeutics Inc. (FHTX)? Wall Street Analysts Think 160.57%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 160.6% in Foghorn Therapeutics Inc. (FHTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of 4.11% and 15.81%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Foghorn Therapeutics Inc. (FHTX) Surges 12.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
Foghorn Therapeutics Inc. (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More
by Zacks Equity Research
Regulatory and pipeline updates from GSK plc (GSK) and Biogen (BIIB) are in focus in the biotech sector.
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -7.35% and 12.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Foghorn Therapeutics Inc. (FHTX) Soars 13.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Foghorn Therapeutics Inc. (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ProPhase Labs, Inc. (PRPH) Soars 7.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -16.95% and 58.64%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -3.33% and 30.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Can Foghorn Therapeutics Inc. (FHTX) Climb 161% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 161.2% upside potential for Foghorn Therapeutics Inc. (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Biotech Stock Roundup: GILD, BLUE, AXSM's Drug Approvals, FHTX Study Update & More
by Zacks Equity Research
Regulatory updates from Gilead (GILD) and Axsome (AXSM) are a few key highlights from the biotech sector during the past week.
Foghorn (FHTX) Phase I AML/MDS Study on Full Clinical Hold
by Zacks Equity Research
Foghorn (FHTX) receives yet another setback as the phase I dose escalation study of FHD-286 in relapsed and/or refractory AML and MDS has been put on full clinical hold.
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -24.53% and 68.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Ironwood Pharmaceuticals (IRWD) Q1 Earnings Miss Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of -22.22% and 2.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Foghorn Therapeutics Inc. (FHTX): Can Its 5.3% Jump Turn into More Strength?
by Zacks Equity Research
Foghorn Therapeutics Inc. (FHTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Wall Street Analysts Think Foghorn Therapeutics Inc. (FHTX) Could Surge 85%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 85% in Foghorn Therapeutics Inc. (FHTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.